Antikine antibodies that bind to multiple CC chemokines
An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
1. An isolated or purified monoclonal antibody produced by hybridoma 18V4F deposited at the ATCC as PTA-11260 or an isolated or purified monoclonal antibody that competes with monoclonal antibody 18V4F for specific binding to MIP-1α (macrophage inflammatory protein 1α), MIP-1β (macrophage inflammatory protein 1β) and RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted); or a fragment thereof that binds to MIP-1a, MIP1-β and RANTES.
2. The isolated or purified monoclonal antibody of claim 1 that is produced by hybridoma 18V4F deposited at the ATCC as PTA-11260.
3. The isolated or purified monoclonal antibody of claim 1 that is a chimeric monoclonal antibody.
4. The isolated or purified monoclonal antibody of claim 1 that is a humanized monoclonal antibody.
5. The isolated or purified monoclonal antibody of claim 1 that is a full-length monoclonal antibody.
6. A fragment of the isolated or purified monoclonal antibody of claim 1 that binds to MIP-1α, MIP1-β and RANTES.
7. The fragment of claim 6 that is an Fab′ or F(ab′)2.
8. The monoclonal antibody or fragment thereof of claim 1 that has been conjugated to an effector moiety, targeting moiety, heterologous protein, toxin, enzyme, cytokine, chemical tag, radiological tag, a substance that increases its biological half-life or a substance that increases its biological availability.
9. A composition comprising (i) the isolated or purified monoclonal antibody or the fragment thereof of claim 1 and (ii) a carrier or excipient.
10. Hybridoma 18V4F deposited at the ATCC as PTA-11260.
11. An isolated or purified monoclonal antibody produced by hybridoma 3C12F deposited at the ATCC as PTA-11261 or an isolated or purified monoclonal antibody that competes with monoclonal antibody 3C12F for specific binding to MIP-1α (macrophage inflammatory protein 1α), MIP-1β (macrophage inflammatory protein 1β) and RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted); or a fragment thereof that binds to MIP-1α, MIP1-β and RANTES.
12. The isolated or purified monoclonal antibody of claim 11 that is produced by hybridoma 3C12F deposited at the ATCC as PTA-11261.
13. The isolated or purified monoclonal antibody of claim 11 that is a chimeric monoclonal antibody.
14. The isolated or purified monoclonal antibody of claim 11 that is a humanized monoclonal antibody.
15. The isolated or purified monoclonal antibody of claim 11 that is a full-length monoclonal antibody.
16. A fragment of the isolated or purified monoclonal antibody of claim 11 that binds to MIP-1α, MIP1-β and RANTES.
17. The fragment of claim 16 that is an Fab′ or F(ab′)2.
18. The monoclonal antibody or fragment thereof of claim 11 that has been conjugated to an effector moiety, targeting moiety, heterologous protein, toxin, enzyme, cytokine, chemical tag, radiological tag, a substance that increases its biological half-life or a substance that increases its biological availability.
19. A composition comprising (i) the isolated or purified monoclonal antibody or the fragment thereof of claim 11 and (ii) a carrier or excipient.
20. Hybridoma 3C12F deposited at the ATCC as PTA-11261.
21. An isolated or purified monoclonal antibody produced by hybridoma 7D12A deposited at the ATCC as PTA-11259 or an isolated or purified monoclonal antibody that competes with monoclonal antibody 7D12A for specific binding to MIP-1α (macrophage inflammatory protein 1α), MIP-1β (macrophage inflammatory protein 1β) and RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted); or a fragment thereof that binds to MIP-1α, MIP1-β and RANTES.
22. The isolated or purified monoclonal antibody of claim 21 that is produced by hybridoma 7D12A deposited at the ATCC as PTA-11259.
23. The isolated or purified monoclonal antibody of claim 21 that is a chimeric monoclonal antibody.
24. The isolated or purified monoclonal antibody of claim 21 that is a humanized monoclonal antibody.
25. The isolated or purified monoclonal antibody of claim 21 that is a full-length monoclonal antibody.
26. A fragment of the isolated or purified monoclonal antibody of claim 21 that binds to MIP-1α, MIP 1-β and RANTES.
27. The fragment of claim 26 that is an Fab′ or F(ab′)2.
28. The monoclonal antibody or fragment thereof of claim 21 that has been conjugated to an effector moiety, targeting moiety, heterologous protein, toxin, enzyme, cytokine, chemical tag, radiological tag, a substance that increases its biological half-life or a substance that increases its biological availability.
29. A composition comprising (i) the isolated or purified monoclonal antibody or the fragment thereof of claim 21 and (ii) a carrier or excipient.
30. Hybridoma 7D12A deposited at the ATCC as PTA-11259.
31. An isolated or purified monoclonal antibody produced by hybridoma 7D1G deposited at the ATCC as PTA-11257 or an isolated or purified monoclonal antibody that competes with monoclonal antibody 7D 1G for specific binding to MIP-1α (macrophage inflammatory protein 1α), MIP-1β (macrophage inflammatory protein 1β) and RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted); or a fragment thereof that binds to MIP-1α, MIP 1-β and RANTES.
32. The isolated or purified monoclonal antibody of claim 31 that is produced by hybridoma 7D1G deposited at the ATCC as PTA-11257.
33. The isolated or purified monoclonal antibody of claim 31 that is a chimeric monoclonal antibody.
34. The isolated or purified monoclonal antibody of claim 31 that is a humanized monoclonal antibody.
35. The isolated or purified monoclonal antibody of claim 31 that is a full-length monoclonal antibody.
36. A fragment of the isolated or purified monoclonal antibody of claim 31 that binds to MIP-1α, MIP1-β and RANTES.
37. The fragment of claim 36 that is an Fab′ or F(ab′)2.
38. The monoclonal antibody or fragment thereof of claim 31 that has been conjugated to an effector moiety, targeting moiety, heterologous protein, toxin, enzyme, cytokine, chemical tag, radiological tag, a substance that increases its biological half-life or a substance that increases its biological availability.
39. A composition comprising (i) the isolated or purified monoclonal antibody or the fragment thereof of claim 31 and (ii) a carrier or excipient.
40. Hybridoma 7D1G deposited at the ATCC as PTA-11257.
41. An isolated or purified monoclonal antibody produced by hybridoma 18P7E deposited at the ATCC as PTA-11258 or an isolated or purified monoclonal antibody that competes with monoclonal antibody 18P7E for specific binding to MIP-1α (macrophage inflammatory protein 1α), MIP-1β (macrophage inflammatory protein 1β) and RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted); or a fragment thereof that binds to MIP-1α, MIP 1-β and RANTES.
42. The isolated or purified monoclonal antibody of claim 41 that is produced by hybridoma 18VP7E deposited at the ATCC as PTA-11258.
43. The isolated or purified monoclonal antibody of claim 41 that is a chimeric monoclonal antibody.
44. The isolated or purified monoclonal antibody of claim 41 that is a humanized monoclonal antibody.
45. The isolated or purified monoclonal antibody of claim 41 that is a full-length monoclonal antibody.
46. A fragment of the isolated or purified monoclonal antibody of claim 41 that binds to MIP-1α, MIP 1-β and RANTES.
47. The fragment of claim 46 that is an Fab′ or F(ab′)2.
48. The monoclonal antibody or fragment thereof of claim 41 that has been conjugated to an effector moiety, targeting moiety, heterologous protein, toxin, enzyme, cytokine, chemical tag, radiological tag, a substance that increases its biological half-life or a substance that increases its biological availability.
49. A composition comprising (i) the isolated or purified monoclonal antibody or the fragment thereof of claim 41 and (ii) a carrier or excipient.
50. Hybridoma 18P7E deposited at the ATCC as PTA-11258.